Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Telmisartan/Amlodipine Besilate

January 12, 2016

Non-proprietary name

Telmisartan/Amlodipine Besilate

Safety measure

Precautions should be revised in the package insert.

In the Clinically significant adverse reaction subsection regarding hepatic function disorder and jaundice of the Adverse reaction section, the following text should be revised (underlined parts are revised):

> Fulminant hepatitis, hepatic function disorder, and jaundice:
> Fulminant hepatitis, hepatic function disorder associated with increased levels of AST (GOT), ALT (GPT), γ-GTP, etc. or jaundice may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be adopted.

In the Clinically significant adverse reaction subsection regarding rhabdomyolysis of the Adverse reaction section, the following text should be revised (underlined parts are revised):

> Rhabdomyolysis characterized by myalgia, feelings of weakness, increased creatinine kinase (creatine phosphokinase), or increased blood and urine myoglobin may occur. Patients should be carefully monitored. If these symptoms are observed, administration of this drug should be discontinued immediately and appropriate measures should be adopted.
> In addition, caution should be exercised for development of acute kidney injury due to rhabdomyolysis.

Pharmaceuticals and Medical Devices Agency
Office of Safety I
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

In the Clinically significant adverse reaction subsection regarding thrombocytopenia and leukopenia of the Adverse reaction section, the following text should be revised (underlined parts are revised):

> Agranulocytosis, leukopenia, and thrombocytopenia:
> Agranulocytosis, leukopenia, or thrombocytopenia may occur. Patients should be carefully monitored through clinical laboratory testing, etc. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be adopted.

Pharmaceuticals and Medical Devices Agency
Office of Safety I
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp